Header Logo

Connection

JOHN KIRKWOOD to Biomarkers, Tumor

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Biomarkers, Tumor.
JOHN KIRKWOOD
Connection Strength
1.640
Biomarkers, Tumor
  1. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res. 2017 Nov 15; 23(22):6888-6892.
    View in: PubMed
    Score: 0.152
  2. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014; 9(2):e87705.
    View in: PubMed
    Score: 0.119
  3. A four-marker signature of TNF-RII, TGF-a, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med. 2014 Jan 23; 12:19.
    View in: PubMed
    Score: 0.119
  4. Advances in adjuvant therapy: potential for prognostic and predictive biomarkers. Methods Mol Biol. 2014; 1102:45-69.
    View in: PubMed
    Score: 0.118
  5. Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients. J Immunol Methods. 2012 Feb 28; 376(1-2):108-12.
    View in: PubMed
    Score: 0.103
  6. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol. 2009 Jun 01; 27(16):2583-5.
    View in: PubMed
    Score: 0.085
  7. STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy. J Invest Dermatol. 2008 Aug; 128(8):1997-2002.
    View in: PubMed
    Score: 0.079
  8. Integrins and cancer. Oncology (Williston Park). 2007 Aug; 21(9 Suppl 3):13-20.
    View in: PubMed
    Score: 0.076
  9. Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy. Oncologist. 2024 Jul 05; 29(7):619-628.
    View in: PubMed
    Score: 0.061
  10. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer. 2002 Sep 01; 95(5):1101-12.
    View in: PubMed
    Score: 0.054
  11. Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II-practical challenges. J Immunother Cancer. 2020 12; 8(2).
    View in: PubMed
    Score: 0.048
  12. Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med. 2020 11; 9(22):8650-8661.
    View in: PubMed
    Score: 0.047
  13. Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I-conceptual challenges. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.047
  14. Developing agents for the therapeutic prevention of melanoma: can the assessment of cutaneous precursor lesions help? Future Oncol. 2020 Mar; 16(9):413-415.
    View in: PubMed
    Score: 0.045
  15. A Th1/IFN? Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 04 01; 26(7):1725-1735.
    View in: PubMed
    Score: 0.044
  16. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 05; 20(5):701-710.
    View in: PubMed
    Score: 0.043
  17. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018 05 14; 6(1):35.
    View in: PubMed
    Score: 0.040
  18. Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. Cancer Prev Res (Phila). 2018 07; 11(7):429-438.
    View in: PubMed
    Score: 0.040
  19. Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. J Immunother Cancer. 2017 08 15; 5(1):67.
    View in: PubMed
    Score: 0.038
  20. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 2017; 5:44.
    View in: PubMed
    Score: 0.037
  21. Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. Clin Cancer Res. 2014 Jun 15; 20(12):3310-8.
    View in: PubMed
    Score: 0.030
  22. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res. 2014 Jun 15; 20(12):3328-37.
    View in: PubMed
    Score: 0.030
  23. Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastasis. 2012 Oct; 29(7):775-96.
    View in: PubMed
    Score: 0.027
  24. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res. 2011 Dec 01; 17(23):7451-61.
    View in: PubMed
    Score: 0.025
  25. Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma. J Immunother. 2010 Apr; 33(3):316-25.
    View in: PubMed
    Score: 0.023
  26. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med. 2009 Jun 17; 7:45.
    View in: PubMed
    Score: 0.022
  27. Predictors of response to interferon therapy. Curr Opin Oncol. 2009 Mar; 21(2):138-43.
    View in: PubMed
    Score: 0.021
  28. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res. 2007 Mar 01; 13(5):1523-31.
    View in: PubMed
    Score: 0.018
  29. Proteomic profile of melanoma cell-derived small extracellular vesicles in patients' plasma: a potential correlate of melanoma progression. J Extracell Vesicles. 2021 02; 10(4):e12063.
    View in: PubMed
    Score: 0.012
  30. Atypical Spitzoid neoplasms: a review of potential markers of biological behavior including sentinel node biopsy. Melanoma Res. 2014 Oct; 24(5):437-47.
    View in: PubMed
    Score: 0.008
  31. Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. PLoS One. 2013; 8(8):e69748.
    View in: PubMed
    Score: 0.007
  32. Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med. 2011 Mar 26; 9:32.
    View in: PubMed
    Score: 0.006
  33. Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol. 2008 Mar 01; 180(5):2967-80.
    View in: PubMed
    Score: 0.005
  34. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol. 2004 Jan 01; 22(1):11-4.
    View in: PubMed
    Score: 0.004
  35. Macroscopic spectral imaging and gene expression analysis of the early stages of melanoma. Mol Med. 1999 Dec; 5(12):785-94.
    View in: PubMed
    Score: 0.003
  36. Molecular analysis of melanoma precursor lesions. Cell Growth Differ. 1996 Dec; 7(12):1733-40.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.